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The use of selected commercial molecular assays for the
microbiological diagnosis of tuberculosis
Zastosowanie wybranych komercyjnych testów molekularnych
w mikrobiologicznej diagnostyce gruźlicy
Abstract
Introduction: We performed a retrospective assessment of the AMPLICOR Mycobacterium tuberculosis (MTB) assay for the
molecular diagnosis of tuberculosis based on our own determinations between 1999 and 2009 and a preliminary assess-
ment of the Xpert MTB/RIF system, which we are currently using.
Materials and methods: The study groups comprised 1875 samples (including 104 inhibited samples) and 213 samples,
respectively.
Results: The sensitivities of the AMPLICOR MTB and the Xpert MTB/RIF assays were 81.9% and 81.8%, respectively, and
their specificities were 97.2% and 99.5%, respectively, versus culture on Loewenstein-Jensen medium. Both assays showed
a considerable difference in sensitivity depending on whether the test samples were smear-positive (AFB+) or smear-
negative (AFB–). The sensitivities of the AMPLICOR MTB and the Xpert MTB/RIF assays were 97.8% and 100.0%, respec-
tively, for AFB+ samples and 58.1% and 50.0%, respectively, for AFB– samples.
Conclusions: Our results confirm full usefulness of the Xpert MTB/RIF assay for routine diagnosis in the case of smear-
positive clinical samples.
Pneumol. Alergol. Pol. 2012; 80, 1: 6–12
Introduction
Nucleic acid amplification (NAA) techniques
are increasingly used for the direct examination of
clinical samples in the laboratory diagnosis of tu-
berculosis, in addition to the standard methods,
which involve microscopy and isolation of myco-
bacteria on a solid or liquid medium. For the past
12 years, NAA-based assays have been included in
the diagnostic algorithm used by our Department.
Between 1999 and 2009 we used the AMPLI-
COR Mycobacterium tuberculosis (MTB) assay (Ro-
che Diagnostics, Switzerland) approved by the
European Centre for Disease Prevention and Con-
trol (ECDC, EU); the AMPLICOR MTB assay is ba-
sed on polymerase chain reaction (PCR) [1]. For the
past year and a half our Department has been using
the Xpert MTB/RIF system (Cepheid, USA), which
utilises real-time PCR [2]. The system was awar-
ded the European Certificate in 2009 and only a
few papers on its use in clinical diagnosis have
been published so far.
A 584-bp DNA fragment within a larger region
encoding for 16S rRNA, common for Mycobacte-
rium spp., was chosen as the target sequence in the
AMPLICOR MTB assay. Of the possible amplifica-
tion products, thanks to the use of a plate coated
with a specific probe, Mycobacterium tuberculosis
complex (MTBC) comprising M. africanum, M.
bovis, BCG, M. microti, M. canetti [3], and M. pin-
nipedii [4] can be detected. The AMPLICOR MTB
assay has the advantage of internal control, which
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of these methods on the same clinical material. Our
study is retrospective in nature: the diagnostic ef-
fectiveness of the AMPLICOR Mycobacterium tu-
berculosis (MTB) assay (Roche Diagnostics, Swit-
zerland) was assessed on the basis of our own de-
terminations performed for more than 10 years. We
then assessed the effectiveness of the Xpert MTB/
RIF system (Cepheid, USA) based on the results
collected since November 2009 in order to gain a
preliminary insight into whether the parameters of
sensitivity and specificity of MTBC genome detec-
tion using the new system match or surpass the
parameters of the previously used assay.
Material and methods
As part of the routine diagnostic procedure, a
smear stained for acid-fast bacilli (AFB) using the
Ziehl-Nielsen method and a culture on Loewenste-
in-Jensen (L/J) solid medium were performed after
liquefaction and decontamination of the clinical
sample using sodium lye with N-acetylcysteine and
sodium citrate, followed by inspissation according
to standard procedure [6]. The cultured mycobac-
terial strains were typed in accordance with the
Centres for Disease Control and Prevention (CDC,
USA) guidelines [7] employing mycolic acid ana-
lysis with the use of high-pressure liquid chroma-
tography (HPLC), as described previously [8, 9]. In
justified cases, genotyping was performed using the
molecular assay GenoType Mycobacterium CM/AS
(Hain Lifescience, Germany) [10]. The molecular
assays AMPLICOR MTB or Xpert MTB/RIF were
used to directly examine the clinical samples in
cases ordered by the clinician.
The AMPLICOR MTB assay was performed in
accordance with the instructions of the manufac-
turer, Roche Diagnostics, Switzerland. All the re-
agents, controls, and plates, coated with specific
probes for the detection of MTBC DNA and for in-
ternal control (IC), were supplied in the kit. One
run requires at least 6 samples and 2 controls (po-
sitive and negative). The assay procedure consists
of 3 stages completed in separate rooms: (1) pre-
paration of the samples, positive control and ne-
gative control, (2) the polymerase chain reaction
proper, and (3) specific detection of the reaction
product and control. In brief, the procedure is as
follows:
1. 100 μl of inspissated clinical sample, after
washing and centrifugation with 500 μl of Re-
spiratory Specimen Wash Solution, was incu-
bated with 100 μl of Respiratory Specimen
Lysis Reagent at 60°C for 45 minutes. The ne-
gative control, MYCO(–)C, and the positive
is a safeguard against false negative results arising
from inhibition of the polymerase. The assay also
has a built-in system (uracil-N-glycosylase) that
secures against contamination by amplicons from
previous determinations, which is the most com-
mon cause of false positive results in routine work.
The real-time PCR technique employed in the
Xpert MTB/RIF system brings a new quality to the
molecular diagnosis of tuberculosis. It allows the
simultaneously use of 5 probes in the amplifica-
tion reaction of the rpoB gene fragment, hence ena-
bling the identification of MTBC and at the same
time the detection of most strains resistant to ri-
fampicin (RIF) [5]. The rpoB gene is a highly con-
servative gene encoding the beta subunit of RNA
polymerase. The enzyme is deactivated by RIF in
sensitive strains. Most mutations in the rpoB re-
gion do not result in a loss of polymerase activity,
but they do make this enzyme insensitive to RIF.
The Xpert MTB/RIF system is fully automated
and all the processes comprising the PCR techni-
que, i.e. DNA release, the polymerase chain reac-
tion proper, and detection of the amplicon, are
integrated in a disposable element (a cartridge)
containing several reaction chambers. Each reac-
tion occurs in a separate chamber and freeze-dried
reagents are released from the capsules as the pro-
cess progresses. This technological solution mini-
mises the risk of contamination (including conta-
mination as a result of transfer of amplicons from
previous determinations) and virtually rules out
the possibility of false positive results. Another
protection measure against false negative results
involves the control of the degree of mycobacte-
rial disintegration and polymerase activity, which
has been indirectly solved in the Xpert MTB/RIF
system as follows: Bacillus globigii spores have
been included as internal control, and a sixth pro-
be detecting B. globigii DNA has been added. Only
clinical samples that give a negative signal for
MTBC and positive signal for B. globigii are true
negative.
The Xpert MTB/RIF system is easy to use and
thanks to being fully automated the duration of
determination does not exceed 2 hours. An addi-
tional positive effect of the automation is the mi-
nimisation of the risk of contamination and the
maximum safety for the staff.
In 2009, the manufacture of the AMPLICOR
MTB assay was discontinued. Of the commercial-
ly available certified NAA assays for the diagnosis
of tuberculosis we selected the Xpert MTB/RIF sys-
tem due to the possibility of simultaneous detec-
tion of resistance to RIF directly in the clinical sam-
ple. It was not, however, possible to compare both
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control, MYCO(+)C, were prepared in paral-
lel with the test sample. The sample and the
controls were neutralised with 100 μl of Re-
spiratory Specimen Neutralisation Reagent.
For the purposes of PCR, 50 μl of the resulting
DNA matrix were collected.
2. 50 μl/reaction of Working Master Mix were
prepared by mixing the following components
in the proportions indicated by the manufac-
turer: MYCO IC (Mycobacterium Internal Con-
trol), AmpErase LD (Low DNA Uracil-N-Glyco-
sylase), and MYCO MMX (Mycobacterium
Master Mix), a reagent containing Taq DNA
polymerase, a mixture of the following nucle-
otides: dATP, dCTP, dGTP, and dUTP, and a
mixture of the following biotinylated primers:
KY18 and KY75. The final PCR volume was
100 μl. The reaction was conducted as follows:
1 cycle, 600 s 50°C/2 cycles, 20 s 98°C, 20 s 62°C,
45 s 72°C/41 cycles, 20 s 94°C, 20 s 62°C, 45 s
72°C/1 cycle, 300 s 72°C/final temperature 72°C.
3. The samples were denatured immediately
after removing from the thermal cycler by ad-
ding 100 μl of Denaturation Solution to each
of the samples. Detection was carried out in
parallel on MTB MWPs (M. tuberculosis Mi-
crowell Plates) and IC MWPs (Internal Control
Microwell Plates) by hybridisation with speci-
fic probes. The hybridisation product was de-
tected using a colour enzymatic reaction with
Avidin-Horseradish Peroxidase Conjugate. All
the stages of the procedure are considered to
have been completed correctly, if extinction
values for both MTB MWP and IC MWP are:
MYCO(–)C ≥ 0.25 and MYCO(+)C ≥ 2.0. Ta-
ble 1 summarises interpretation of the results.
Determination takes 7–8 hours to complete,
excluding pretreatment of the clinical samples.
The Xpert MTB/RIF assay was performed in
accordance with the instructions of the manufac-
turer (Cepheid, USA), which enable determination
of liquefied, decontaminated and inspissated cli-
nical samples as well as samples without pretreat-
ment. A rule was adopted to determine samples
after pretreatment and a decision not to apply this
rule was made only in isolated justified cases.
1.5 ml of the sample reagent (SR) was added to
0.5 ml of the sample, mixed and incubated for 15
minutes at room temperature, and mixed again
between 5 and 10 minutes of incubation. The mi-
xture was then transferred to the cartridge and the
cartridge was placed in the GeneXpert system, con-
trolled by the computer, and the reaction, which
took 2 hours to complete, was initiated. The pro-
cess was fully automated and the results were in-
terpreted by integral software in accordance with
the following algorithm:
1. The result is positive for MTBC if at least 2
out of 5 rpoB probes give a positive signal no
later than in the two subsequent cycles.
2. The result is negative for MTBC if condition 1
is not met and the probe for B. globigii gives a
positive signal.
3. Samples negative for both MTBC and B. glo-
bigii are classed as indeterminable.
4. Resistance to RIF is identified if condition 1
is met and at least 1 out of the remaining 3
rpoB probes is negative.
Results
From 12 January 1999 to 16 November 2009 a
total of 1875 clinical samples were examined using
the AMPLICOR MTB assay. In 1771 cases the po-
lymerase chain reaction was not inhibited and the
results were diagnostically relevant. Concordant
results using the AMPLICOR MTB assay and the
L/J culture were obtained for 90.5% (1697/1875) of
the samples tested: in both tests, there were 127
positive and 1570 negative samples. Discordant
results were obtained for 4.0% (74/1875) of the
samples. For 46 samples, the AMPLICOR MTB as-
say results were positive but cultures were negati-
ve. In 28 cases, tuberculosis was confirmed by L/J
culture only with the AMPLICOR MTB assay be-
ing negative. In most cases these were bacteriosco-
py-negative materials (24 samples), but in 2 cases
the samples were positive on bacterioscopy. The
results are summarised in Table 2.
Table 1. AMPLICOR MTB Test (Roche Diagnostics, Switzerland) — interpretation of results
Mtbc A450 IC A450 Interpretation
< 0,35 ≥ 0,35 Negative result. MTB DNA not detected
< 0,35 < 0,35 Inhibitory Specimen. MTB DNA, if present, would not be detectable
≥ 0,35 Any Positive result. Specimen is positive for the presence of MTB
Mtbc — Mycobacterium tuberculosis complex, IC — internal control
Aleksandra Safianowska et al., The use of selected commercial molecular assays for the microbiological diagnosis of TB
9www.pneumonologia.viamedica.pl
Based on the above results, we calculated the
sensitivity and specificity of the AMPLICOR MTB
assay obtaining the following values: 81.9% (127/
155) and 97.2% (1570/1616), respectively. The sen-
sitivity of the molecular assay was then analysed
in groups. For the 225 samples for which bacte-
rioscopy was positive (AFB(+) samples), the sensi-
tivity of the AMPLICOR MTB assay was 97.8% (91/
93). In the group of the remaining 1546 samples
(1499 AFB(–) samples and 47 samples for which,
for justified reasons, bacterioscopy was not perfor-
med), the sensitivity of the assay was 58.1% (36/62).
In one case, from an AFB(+) sample which
was initially positive for MTBC in the AMPLICOR
MTB assay an NTM strain was cultured, which was
subsequently typed by HPLC as M. chelonae. The
examination was repeated using another molecu-
lar test, GenoType Mycobacterium CM/AS, which
yielded a result that was concordant with the
AMPLICOR MTB assay, confirming the presence
of MTBC DNA. It was eventually established that
the M. chelonae strain was a contaminant.
In the tested group, the PCR was inhibited in
104 cases. Inhibition was most common in the bron-
choalveolar lavage fluid (BALF) and in the urine.
For 23% of the BALF samples and 12% of the urine
samples tested no PCR result was obtained.
The Xpert MTB/RIF system is routinely used
in the laboratory diagnosis of tuberculosis in our
Department at present. Table 3 summarises results
for 213 clinical samples. In 208 cases (97.6%), the
results of the new molecular assay and those of
cultures were concordant. In 18 cases, we obtained
positive results both in the Xpert MTB/RIF system
and in the L/J culture. In both tests, 190 clinical
samples were negative. Of the remaining 5 sam-
ples for which the results were discordant, MTBC
strains were cultured from 4 AFB(–) samples de-
spite the negativity in the molecular assay. The sen-
sitivity of the assay was estimated at 81.8% (18/
22) and its specificity at 99.5% (190/191). Taking
bacterioscopy results into account, sensitivity was
100% (14/14) for samples positive with Ziehl-Ne-
elsen stain and 50% (4/8) for bacterioscopy-nega-
tive samples.
In the Xpert MTB/RIF system, no cases of in-
hibition reaction occurred: in a few cases (3 spu-
tum samples, 1 bronchial lavage fluid sample, 1
bronchial discharge sample) the result was consi-
dered indeterminable by the system, but reliable
results were obtained on retest.
In the study group of clinical samples, non-
tuberculous strains were cultured in 7 cases with
no cross-reaction being observed in any instan-
ce. No resistance to RIF was identified in the stu-
dy group.
Discussion
Our results indicate that both the sensitivity
and the specificity of the AMPLICOR MTB assay
were very high: 81.9% and 97.2%, respectively.
Table 2. Results of the AMPLICOR MTB Test (Roche Diagnostics, Switzerland)
Microscopy AFB(+) AFB(–) Not performed Total
PCR(+) L/J(+) 91 33 3 127 173
L/J(–) 31 12 3 46
PCR(–) L/J(+) 2 24 2 28 1598
L/J(–) 101 1430 39 1570
Total L/J(+) 93 57 5 155 1771
L/J(–) 132 1442 42 1616
AFB — acid fast bacilli, L/J — Loewenstein-Jensen medium, PCR — polimerase chain reaction
Table 3. Results of the Xpert MTB/RIF (Cepheid, USA)
Microscopy AFB(+) AFB(–) Not performed Total
Xpert(+) L/J(+) 14 4 0 18 19
L/J(–) 1 0 0 1
Xpert(–) L/J(+) 0 4 0 4 194
L/J(–) 7 181 2 190
Total L/J(+) 14 8 0 22 213
L/J(–) 8 181 2 191
AFB — acid fast bacilli, L/J — Loewenstein-Jensen medium
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While assay specificity was not affected by whe-
ther the sample was rich or poor in mycobacteria,
assay sensitivity depended on the type of clinical
material and was high (97.8%) for AFB(+) samples
and much lower (58.1%) for AFB(–) samples. With
these parameters characterising the diagnostic ef-
fectiveness of the AMPLICOR MTB assay, a posi-
tive result confirms tuberculosis for a sample po-
sitive for Ziehl-Neelsen stain and is strongly sug-
gestive of tuberculosis if the smear is negative. An
isolated negative result of the assay does not rule
out tuberculosis if the sample is negative in mi-
croscopy. If the sample is positive for Ziehl-Neel-
sen stain, a negative result of the AMPLICOR MTB
assay strongly suggests the presence of non-tuber-
culous mycobacteria. Our results are consistent
with bibliographical data [11, 12].
The Xpert MTB/RIF system was implemented
by us in November 2009, half a year after it had
been approved for routine diagnosis in the Euro-
pean Union by the ECDC. True results (true posi-
tive and true negative results) were obtained in
97.6% of the cases, which is slightly higher than
the true result rate for the AMPLICOR MTB assay
(90.5%). In our study, the specificity of the Xpert
MTB/RIF system was slightly higher than that of
the AMPLICOR MTB assay (99.5% vs. 97.2%),
while the sensitivity was on a similar level (81.8%
vs. 81.6%). After including microscopy results in
the analysis, the sensitivity for both systems was
very high (100% for Xpert MTB/RIF and 97.8% for
AMPLICOR MTB) and much lower for samples
poor in mycobacteria and negative on bacteriosco-
py (50.0% for Xpert MTB/RIF and 58.1% for AM-
PLICOR MTB). It seems, however, that due to the
small number of 8 AFB(–) samples which were
examined using the Xpert MTB/RIF system, dra-
wing conclusions on the sensitivity of this system
for samples poor in mycobacteria is not justified.
In connection with the use of real-time PCR one
should rather expect a much higher diagnostic sen-
sitivity in the Xpert MTB/RIF system compared to
the traditional NAA assays. Other team of investi-
gators has obtained much higher sensitivity
(72.5%) for AFB(–) clinical materials while exami-
ning isolated samples. Sensitivity was even higher
(85.1%) if two samples were tested with the Xpert
MTB/RIF system and even reached 90.2% when
three examinations were performed [13].
Our study indicates that some of the diagno-
stic parameters of the Xpert MTB/RIF system are
slightly higher than those of the AMPLICOR MTB.
However, taking into account the World Health
Organization recommendation [14] to use the Xpert
MTB/RIF system in the first step of the laboratory
procedure in the diagnosis of tuberculosis in adults
suspected of multidrug resistant tuberculosis (MDR
TB) or tuberculosis in the course of HIV infection
and, possibly, for other patients, as a second test
for AFB(+) samples in the smear, it seems neces-
sary for us to conduct further research on the sen-
sitivity of the method in AFB(–) samples poor in
mycobacteria.
Based on our study we cannot address the
specificity of the Xpert MTB/RIF system if mixed
mycobacterial strains are present in the sample, as
those did not occur. Helb et al. [15] conclude that
the Xpert MTB/RIF system is characterised by a
high specificity and the ability to detect MTBC stra-
ins even in samples contaminated with non-tuber-
culous mycobacteria. In the cited study, none of
the 22 non-tuberculous mycobacterial strains te-
sted, out of the 22 Mycobacterium species, cross-
reacted. The test correctly detected MTBC in the
presence of M. avium, M. intracellulare, M. kansa-
sii, and M. malmoense.
Our assessment of the Xpert MTB/RIF system
in terms of detection of resistance to RIF remains
another open question. In regions with high rates
of MDR TB, defined as simultaneous resistance to
RIF and isoniazid (INH), 70–95% of M. tuberculo-
sis strains resistant to RIF had a mutation in one
of the following three loci of the rpoB gene: 516,
526, or 531 [16, 17]. Prammananan et al. presen-
ted a discussion in their study on the prevalence
of various mutations determining resistance to RIF
depending on the geographical region [18]. Because
the emergence of resistance to INH usually prece-
des resistance to RIF, the latter is often treated as a
substitute marker of multidrug resistance [19]. In
regions where MDR TB is rare, the use of resistan-
ce to RIF as a marker of multidrug resistance de-
pends on the prevalence of monoresistance to RIF
in a given population [20]. Augustynowicz-Kopeć
showed that in the Polish population, in previo-
usly treated patients, genetically determined resistan-
ce to RIF may be a substitute marker of MDR TB [21].
It seems, therefore, that the Xpert MTB/RIF system
may be useful for determining at least secondary re-
sistance of the MDR type, although we could not
address this issue in our study as no strains resistant
to RIF were present in the study group.
Conclusions
1. Our study assessed the use of the AMPLICOR
MTB assay and the new system, Xpert MTB/RIF,
for the molecular diagnosis of tuberculosis.
2. Our results demonstrate complete usefulness
of the Xpert MTB/RIF system for routine dia-
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gnosis of clinical samples, positive in the mi-
croscopic examination of the smear (i.e.
AFB(+) samples).
3. Determination of the sensitivity of the Xpert
MTB/RIF system for smear-negative samples
requires further research with participation of
a larger number of patients.
4. It is necessary to determine the specificity of
the Xpert MTB/RIF system for M. tuberculo-
sis strains contaminated with environmental
mycobacteria and to examine the effective-
ness of the system for the detection of stra-
ins resistant to RIF.
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